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ABSTRACT
BACKGROUNDS/AIMS: Double strand nuclear factor-κB decoy oligodeoxynucleotide 
(NF-κB-Decoy) had been investigated as a potential therapeutic approach in ulcerative 
colitis. Here we confirm that NF-κB-Decoy inhibits inflammatory cytokines production 
in vitro, and report initial studies of the use of liposome-conjugated NF-κB-Decoy to 
treat dextran sodium sulphate (DSS)-induced colitis. METHODS: (1) Peripheral blood 
samples or cultured Colo 205, colon cancer cels were pretreated with NF-κB-Decoy and 
stimulated with lipopolysaccharide. (2) Eight-weeks-old female BALB/C mice were fed 
4% DSS in drinking water for 7 days. Intra-colonic administration of liposome-
conjugated NF-κB-Decoy started at the same time as DSS treatment, and continued for 
14 days. RESULTS: (1) In the peripheral blood, NF-κB-Decoy significantly inhibited 
interleukin (IL)-6 production (Tukey test, p<0.05). In the cultured cels, NF-κB-Decoy 
significantly reduced IL-8 production (t-test, p<0.01). (2) During administration of DSS, 
mortality rate between NF-κB-Decoy treated and control mice (72.4% and 57.6% 
respectively) was not significantly diferent, and body weight loss and histopathological 
dameges were similar in both groups. But, after discontinuation of DSS, NF-κB-Decoy-
treated mice regained body weight significantly earlier than did control mice. 
CONCLUSIONS: NF-κB-Decoy actualy inhibited IL-6 and IL-8 production in vitro. 
Although liposome-conjugated NF-κB-Decoy could not show amelioration in DSS mice 
model, NF-κB-Decoy treated mice showed earlier regain of body weight.
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INTRODUCTION
　Nuclear factor-κB (NF-κB) is a key tran-
scriptional regulator of inflammation and 
immune response. Activation of NF-κB pro-
motes the expression of inflammatory cytoki-
nes such as tumor necrosis factor-α (TNF-α), 
interleukin (IL) -1β,　IL-6 and IL-8 in the 
inflamed colonic mucosa characteristic of 
ulcerative colitis1)-5). Double-stranded NF-κB 
decoy oligodeoxynucleotide (NF-κB-Decoy) has 
been investigated as a potential strategy to 
regulate NF-κB activa-tion6)-8). NF-κB-Decoy 
attaches to the promoter site to which NF-κB 
binds and consequently attenuates the tran-
scriptional activity of NF-κB. Antisense oligo-
nucleotide to NF-κB was earlier proposed as a 
strategy to attenuate the efects of NF-κB9)-11), 
but has not yet reached clinical application. 
Theoretical considerations suggest that NF-κB-
Decoy might be more stable and work more 
quickly than antisense to NF-κB.
　Intra-colonic administration of bare NF-κB-
Decoy has been reported to result in ameliora-
tion of symptoms in models of colitis induced 
by trinitrobenzene sulphonic acid (TNBS), 
oxazolone  and  dextran  sodium  sulphate 
(DSS)12),13). De Vry et al reported that NF-κB-
Decoy facilitated healing of TNBS colitis and 
inhibited expression of the mRNAs for inflam-
matory cytokines12). However, to work wel, NF-
κB-Decoy must be distributed intracelularly14). 
De Rosa et al reported that intracelular 
uptake of NF-κB-Decoy was enhanced by 
administration in microspheres15). Therefore, 
we investigated the eficacy of liposomal-
conjugated NF-κB-Decoy in a mouse model of 
DSS-induced colitis. In addition, to explore 
potential mechanisms, we investigated the 
efect of NF-κB-Decoy on inflammatory cyto-
kines production by peripheral blood and 
cultured epithelial cels.
METHODS
Chemicals
　NF-κB-Decoy was provided by Anges MG 
Inc. (Osaka, Japan) by courtesy of Professor 
Ryuichi Morishita. The sequence of the NF-κB-
Decoy used in this study is 5’-CCTTGAAGGGA
TTTCCCTCC-3’and 3’-GGAACTTCCCTAAAG
GGAGG-5’. The underlined sequences are 
identical to the binding site of NF-κB on the 
promoters of its target genes. FuGENE6 
(Roche Diagnostics, Tokyo, Japan) was used as 
transfection reagent in in vitro experiments. 
Liposome COATSOME: EL-01-C (NOF Co, 
Tokyo, Japan) was used as carrier for intra-
colonic administration. DSS (ICN Biochemi-
cals Inc, Tokyo, Japan) which molecular 
weights were 36000-50000 kDa, was prepared. 
To stimulate peripheral blood and cultures 
cels, lipopolysaccharide (LPS) from E. Coli 
O5:B55 (Sigma Chemical Co, St Louis, MO, 
USA). Each cytokines were measured using 
ELISA kit (R&D Systems, Minneapolis, MN, 
USA).
Peripheral blood
　Peripheral blood samples with heparin were 
colected from healthy volunteers and RPMI 
1640 containing 10% fetal bovine serum were 
prepared as culture medium. In the wels of 24 
wel culture plates, 0.1 ml of blood sample was 
suspended in the 0.9 ml of culture medium. 
Blood suspension was treated various concen-
tration of NF-κB Decoy and/or 3 μl of 
FuGENE6 2 hours prior to LPS stimulation. 
After adding 1 ng of LPS per wel (final 
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concentration of 1 μg/ml), 4 hours incubation 
at 37°C under 5% CO2, was done. Then the 
supernatant was colected by centrifugation at 
3000 rpm at 4°C for 5 min and was stored -80°C 
until assay. TNF-α, IL-6, IL-1β, and IL-8 were 
measured by using an ELISA kit (R&D 
Systems, Minneapolis, MN, USA).
Cultured cells
　The Colo 205 colon cancer cel line was 
provided by the Cel Source Center of Geriatric 
Medicine, Tohoku University School of medi-
cine. Cels were cultured in RPMI 1640 
(Invitorogen, Tokyo, Japan) containing 1mM L-
glutamine, 10% FBS, and 12.5 μg/ml gentami-
cin. Cels (3x105 cels/wel) were prepared in 
each wel of 6-wel culture plate and incubated 
for 24 hours at 37°C under 5% CO2. Then the 
culture medium was changed to RPMI 1640 
containing 10% FBS but without gentamicin. 
NF-κB-Decoy was added to the wels at a final 
concentration of 1 μg/ml and incubation was 
continued for 2 hours. Then LPS solution was 
added to the wels at a final concentration of 1
μg/ml. After 4 hours incubation at 37°C under 
5% CO2, supernatant was colected by centrifu-
gation at 3000 rpm at 4°C for 5 min and was 
stored-80°C until assay. IL-8, TNF-α, IL-1β, 
and IL-6 were measured in the supernatant. 
Cel viability was verified by Trypan Blue 
staining.
Animal model
　These animal experiments were approved by 
Laboratory Animal Center, Yamagata Univer-
sity Faculty of Medicine. BALB/C mice (female, 
8 weeks) (CLEA Japan Inc., Tokyo, Japan) 
were used. To induce colitis, mice were alowed 
free access to 4% DSS solution in drinking 
water for 7 days (from Day 1 to Day 7). For 
treatment, NF-κB-Decoy was dissolved in 
liposome solution at a final concentration of 2 
mg/ml with distiled water. Preparation of 
liposome-conjugated NF-κB-Decoy were fol-
lowed the technique recommended by NOF Co. 
Saline was used as control. For 14 days (from D 
1 to D 14), 0.4 ml of each solution (800 μg/body 
of NF-κB) was administrated intracolonicaly 3 
cm into the colon by a thin and soft 
polyurethane tube. Body weight and mortality 
rate was evaluated. In a separate experiment, 
mice were sacrificed at Day 10, and histopa-
thological changes16) and serum cytokines 
levels in both groups were examined.
Statistics
　Tukey test was applied to analyze examina-
tions of peripheral blood. Student’s t test was 
used to analyze body weight and IL-8 
concentrations in culture cels. Mortality rate 
were tested by χ2 or Fischer’s exact calcula-
tion. IL-6 in DSS induced colitis and histologi-
cal index were evaluated by Mann-Whitney’s 
U test. Diference with p values less than 0.05 
were considered as significant.
RESULTS
Peripheral blood
　On stimulation with LPS, peripheral blood 
produced TNF-α, IL-1β, and IL-6 but not IL-
8. NF-κB-Decoy did not inhibit production of 
TNF-α (Figure 1a). But when NF-κB-Decoy 
was treated with FuGENE6, TNF-α produc-
tion was significantly inhibited. In contrast, 
NF-κB-Decoy significantly inhibited produc-
tion of IL-6 and stronger inhibition were 
observed using FuGENE6 (Figure 2a). In 
another experiments, it was confirmed that 
FuGENE6 itself did not influence on the TNF-
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α (Figure 1b) and IL-6 (Figure 2b) production. 
IL-1β had been measurable, but NF-κB-Decoy 
did not significantly inhibit production of IL-1
β even with FuGENE6 treatment. 
Culture cells
　Cultured Colo 205 cels produced IL-8 on 
stimulation with LPS. NF-κB-Decoy signifi-
　Fig. 1b. Influence of FuGENE6 on the produc-
tion of TNF-α in the peripheral blood
Blood samples were pretreated with or without 
FuGENE6. FuGENE6 itself did not suppress 
TNF-α production of blood cels but NF-κB-
Decoy significantly inhibited production of 
TNF-α (mean ± SD) (Tukey-test, p<0.01). 
“Decoy” indicated NF-κB-Decoy treatment 
(n=12) and “Control” indicated control (n=12).
　Fig. 1a. Effect of NF-κB-Decoy on the produc-
tion of TNF-α in the peripheral blood
Blood samples were pretreated with NF-κB-
Decoy (with or without FuGENE6) at final 
concentration of 100 and 1 μg/ml for 2 hours. 
After 4 hours incubation with LPS, TNF-α 
concentrations of supernatant were measured 
(mean ± SD). NF-κB-Decoy significantly inhib-
ited production of TNF-α in the cases with 
FuGENE6 (Tukey-test, p<0.05). “Decoy” indi-
cated NF-κB-Decoy treatment (n=12) and 
“Control” indicated control (n=12).
　Fig. 2a. Effect of NF-κB-Decoy on the produc-
tion of IL-6 in the peripheral blood
Blood samples were pretreated with NF-κB-
Decoy (with or without FuGENE6) at final 
concentration of 100 and 1 μg/ml for 2 hours. 
After 4 hours incubation with LPS, IL-6 
concentrations of supernatant were measured 
(mean ± SD). NF-κB-Decoy significantly inhib-
ited production of IL-6 (Tukey-test, p<0.05). 
“Decoy” indicated NF-κB-Decoy treatment 
(n=12) and “Control” indicated control (n=12).
　Fig. 2b. Influence of FuGENE6 on the produc-
tion of IL-6 in the peripheral blood
Blood samples were pretreated with or without 
FuGENE6. FuGENE6 itself did not suppress 
TNF-α production of blood cels (mean ± SD) 
(Tukey-test, p<0.05). “Decoy” indicated NF-κ
B-Decoy treatment (n=6) and “Control” 
indicated control (n=6).
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cantly inhibited production of IL-8 (t-test, 
p<0.01) (Figure 3). TNF-α, IL-6 and IL-1β 
were not measurable in this experiment.
Liposome-conjugated NF-κB in DSS 
induced colitis
　We performed three separate sets of studies 
of survival and body weight. In total, 29 mice 
were treated with liposome-conjugated NF-κB-
Decoy (treated mice) and 33 mice were 
assigned to the control group. During the study 
periods, 21 of 29 treated mice and 19 of 33 
control mice died. These mortality rates were 
not significantly diferent (χ2 test). The change 
in body weight of surviving mice in both 
groups is shown in Figure 4. The body weight 
of the NF-κB treated mice decrease similarly 
to the control mice until Day 9, but after Day 
10 the treated mice showed earlier regain of 
body weight compared with the control mice (t-
test, p<0.05). There was a significant difer-
ence at Day 10, 11, and 12, but on Day 13 and 
14 the body weight of both groups became 
similar.
　In a separated set of similar studies, mice 
were sacrificed on Day 10. Two sections of each 
colon, representing the proximal and distal one-
thirds, were prepared and inflammation was 
scored histologicaly. Based on the histological 
colitis scoring method, score (mean ± SD) of 
the NF-κB-Decoy treated group (n=6) and 
control group (n=10) were 7.3 ± 2.8 and 7.5 ± 
2.6, respectively (Table 2). These values are not 
significantly diferent, indicating that NF-κB-
Decoy treatment did not ameliorate the 
histopathological changes characteristic of 
DSS-induced colitis. Then serum concentra-
tions of IL-6 of mice were measured. As a 
number of serum samples were was smal and 
varied widely, validity could not be evaluated. 
　Fig. 4. Change of body weights of mice in DSS 
colitis model
Mice were fed 4% DSS in drinking water for 
7 days, and intra-colonic administration of 
liposome-conjugated NF-κB decoy oligodeoxynu-
cleotide started at the same time of beginning of 
DSS water-feeding for 14 days. Closed square 
with brake line showed NF-κB decoy oligode-
oxynucleotide treated mice and open diamond 
with solid line showed control mice (mean ± 
SD). On the day 10, 11, and 12, significant 
higher body weight revealed in NF-κB-Decoy 
treated group (*; t-test, p<0.05).
　Fig. 3. Effect of NF-κB-Decoy on the produc-
tion of IL-8 in cultured cels
Colo 205 cels were pretreated with NF-κB-
Decoy at final concentration of 1 μg/ml for 2 
hours. After 4 hours incubation with LPS, IL-8 
concentrations were measured in the super-
natant (mean ± SD). NF-κB-Decoy significantly 
inhibited production of IL-8 in cultured cels (t-
test, p<0.01). “Decoy” indicated NF-κB-Decoy 
treatment (n=6) and “Control” indicate control 
(n=6).
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However, NF-κB treated mice revealed 127 ± 
158 pg/ml and 76 ± 42 pg/ml control mice done 
so (Table 2).
DISCUSSION
　At first, we confirmed that NF-κB-Decoy 
had certain inhibitory efects on TNF-α, IL-6, 
and IL-8 production in vitro. In peripheral 
blood experiments, we should properly use 
monocytes derived from inflammatory mucosa. 
But, as many inflammatory cels are supplied 
from peripheral blood, we have chosen periph-
eral whole blood as substitutes of inflamma-
tory mucosal cels, in this preliminary in vitro 
study. In addition, we chose colon cancer cel 
line as colonic epithelial cels. As IL-6 
production from peripheral blood and IL-8 
production from epithelial cels were particu-
larly inhibited, NF-κB-Decoy may be practi-
caly promising in the treatment for inflamma-
tory bowel disease. 
　NF-κB-Decoy should enter inside the cels to 
work wel. We showed that treatment of 
transfection reagent enhanced the inhibitory 
efect. In fact, intra-bronchiole administration 
of NF-κB-Decoy could not show eficacy in 
bleomycin induced pneumonia and it pre-
sumed to be problem of insuficient intra-
celular distribution17). Therefore it is an 
important issue that eficient delivery systems 
of NF-κB-Decoy should be established. Con-
cerning NF-κB-Decoy delivery system, De 
Rosa et al reported that intracelular uptake of 
NF-κB was enhanced applying microsphere15). 
So far it had been reported that an intra-
colonic administration of bare NF-κB-Decoy 
was efective in the animal models of 
inflammatory bowel disease12),13). Hence, based 
on this NF-κB-Decoy delivery system, we 
performed a preliminary study applying 
liposome-conjugated NF-κB-Decoy in vivo.
　As NF-κB-Decoy is a double strand oligode-
oxynucleotide, it might be expected to be 
stable. However, the half-life of NF-κB-Decoy 
is 26 minutes after intravenous administration 
　Table 1. Mortality rate in the DSS-induced model of colitis
mortality ratesurvivedead
(72.4%)821(n=29)NF-κB-Decoy
(57.6%)1419(n=33)Control
Mice were fed 4% DSS in drinking water for 7 days, and intracolonic treatment with liposome-
conjugated NF-κB-Decoy was initiated at the beginning of DSS administration and continued for 14 
days. Mortality refers to the period of DSS administration. The mortality rates in the two groups 
were not significantly different (χ2 test).
　Table 2. Concentration of serum IL-6 and histological score after discontinuation of DSS treatment
Control (n=10)NF-κB-Decoy (n= 6)
76 ± 42127 ± 158Serum IL-6 (pg/ml)
7.5 ± 2.67.3 ± 2.8Histological Score
As a separate experiment, mice were sacrificed at Day 10. There were not significant difference in 
serum IL-6 levels and histological colitis scores between liposome-conjugated NF-κB-Decoy and 
control mice group.
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(information from Anges MG Co., Osaka, 
Japan). Therefore, topical (i.e. intracolonic) 
administration appears necessary for treat-
ment of colitis. Analogously, in atopic dermati-
tis, where the target cels for NF-κB-Decoy are 
epidermal macrophages, topical NF-κB-Decoy 
ointment applied to the skin showed eficacy in 
an atopic mouse model18). Recently, to improve 
the stability of NF-κB-Decoy, ribbon-type of 
the decoy oligodeoxynucleotides had been 
developed and investigated19).
　In previous reports of the use of NF-κB 
decoy oligonucleotides in models of colitis, 
TNBS- and oxazolone-induced models were 
described in ful. Precisely and suficient 
improvements were reported not only in the 
histopathological evaluations but also mRNA 
expressions of inflammatory cytokines12),13), 
whereas relatively little information was 
provided on the DSS-induced model12). Topical 
(intracolonic) administration should be practi-
cal for the distal type of ulcerative colitis, and 
the DSS-induced colitis model is generaly 
employed as an animal model of ulcerative 
colitis. Consequently, we chose the DSS-
induced colitis model for this study.
　To establish the model, we used 5% DSS in 
water in initial experiments. However, al mice 
were lost within 14 days. The present study 
used 4% DSS in water, which also appears to be 
a severe insult as the mortality rate remained 
high. Under these conditions, mortality was 
not improved by NF-κB-Decoy-treatment. In 
addition, decrease of body weight, histopa-
thological scores, and increase of IL-6 levels 
during DSS intake were not improved in the 
NF-κB-Decoy-treated mice. As a result, we 
could not reveal amelioration of colitis by NF-κ
B-Decoy. As an only benefit of NF-κB-Decoy 
treatment, we could observe that NF-κB-
Decoy-treated mice regained body weight more 
quickly after discontinuation of DSS treat-
ment. De Vry et al also mentioned that NF-κB-
Decoy might contribute to the early recover in 
TNBS colitis model12).
　We must discuss that liposome-conjugate NF-
κB-Decoy failed to show improvements in DSS 
mouse model, contrary to previous reports. It 
may firstly rise up as an issue that DSS colitis 
model used in this study might be too severe. 
In fact, mortality rate showed more than 50%. 
If we attempt to make a clinical application of 
NF-κB-Decoy for the patients with ulcerative 
colitis, distal colitis type with mild inflamma-
tion may be indicated. Hence, we might have 
chosen mild colitis model. Secondary, liposome 
itself was possibly to cause deterioration of 
inflammation. However, we preliminary evalu-
ated liposome solution did not exacerbate 
colitis in smal number of animals, although 
data had not been shown.
　Recently, Xiang et al reported that NF-κB-
Decoy treatment ameliorated 5% DSS-induced 
murine colitis model20). They used the same 
decoy oligodeoxynucleotides as ours, which 
were not liposome conjugated. It was thought 
that relatively smal molecular weight of DSS 
realized the adequate colitis model. In future, 
using the appropriate colitis model, we must 
investigate whether the liposome conjugated 
NF-κB-Decoy is truly more efective than the 
bare NF-κB-Decoy.
　Prior to NF-κB-Decoy, successful treatments 
of NF-κB p65 antisense oligonucleotides in 
TNBS or DSS colitis models9)-11). In addition, 
NF-κB p65 antisense oligonucleotides actualy 
inhibited production of pro-inflammatory cyto-
kines in lamina propria mononuclaer cels 
drived from ulcerative colitis patients21). In 
future, comparing NF-κB-Decoy and NF-κB 
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p65 antisense oligonucleotides, we may eluci-
date which is more promising to medical 
treatment for ulcerative colitis.
CONCLUSIONS
　In conclusion, it had been confirmed that 
NF-κB-Decoy actualy inhibited production of 
inflammatory cytokines such as TNF-α, IL-6 
and IL-8 in vitro. On the other hand, liposome-
conjugated NF-κB-Decoy could not show 
histopathological amelioration in DSS mice 
model, but NF-κB-Decoy treated mice showed 
earlier regain of body weight compared with 
the control mice.
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